Ian Estepan | SVP, Chief of Staff and Corporate Affairs |
Doug Ingram | President and CEO |
Sandy Mahatme | EVP, CFO and Chief Business Officer |
Bo Cumbo | EVP and Chief Commercial Officer |
Gilmore O'Neill | EVP, R&D and Chief Medical Officer |
Louise Rodino-Klapac | SVP, Gene Therapy |
Salveen Richter | Goldman Sachs |
Brian Abrahams | RBC Capital Markets |
Tazeen Ahmad | Bank of America Merrill Lynch |
Debjit Chattopadhyay | H.C. Wainwright |
Gena Wang | Barclays Capital |
Joseph Schwartz | SVB Leerink |
Christopher Marai | Nomura |
Shawn Egan | Citi |
Maxwell Skor | Morgan Stanley |
Vincent Chen | Bernstein |
Tim Lugo | William Blair |
Liisa Bayko | JMP Securities |
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics First Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded.
And now I would like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs.